NewsBenzingaAmgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points Benzinga 2026.10.20 13:06 (GMT+0) Open on Benzinga Other news PancakeSwap Opens 'The Flip' Vote With CAKE Supply Condition ServiceNow's Quarterly Earnings Preview: What You Need to Know PTC's Q4 2026 Earnings: What to Expect SpaceX Becoming a Bitcoin Hodler? Elon Musk-Led Rocket Company Keeps All BTC, Now Worth $1.57 Billion Binance to Remove Premium Index from Funding Rate Calculation for US Stock TradFi Perpetual Contracts During Affected Period Stock Market: Will S&P 500 Open Up or Down Today?
SpaceX Becoming a Bitcoin Hodler? Elon Musk-Led Rocket Company Keeps All BTC, Now Worth $1.57 Billion
Binance to Remove Premium Index from Funding Rate Calculation for US Stock TradFi Perpetual Contracts During Affected Period
